KRON(Delisted)
Kronos Bio (KRON) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Kronos Bio market cap is -- and enterprise value is --.
Share Statistics
Kronos Bio has 60.97M shares outstanding, with a free float of 39.45M.
Valuation Ratios
Kronos Bio's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Liquidity
Kronos Bio's current ratio is 12.93, quick ratio is 12.93, and cash ratio is --, showing its short-term liquidity position.
Return on Capital
Kronos Bio's ROE is --, ROA is --, and ROIC is --, showing its return on capital profile.
Profitability
Kronos Bio gross margin is 100.00%, operating margin is -765.18%, and net margin is -701.53%.
Cost Structure
Kronos Bio spends 397.72% of revenue on R&D and 252.74% on SG&A.
Operating Efficiency
Kronos Bio's asset turnover is --, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
Kronos Bio's revenue is 9.19M, gross profit is 9.19M, net income is --, and EBITDA is --.
Balance Sheet
Kronos Bio's total debt is --, net debt is --, total equity is --, and cash is --.
Cash Flow Statement
Kronos Bio's operating cash flow is -54.38M, free cash flow is -54.38M, and CapEx is --.
Dividends & Yields
Kronos Bio dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Kronos Bio's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A company that develops therapeutics for cancer by targeting dysregulated transcription
Per Share Metrics
Kronos Bio's EPS is --, book value per share is --, and free cash flow per share is --.
